Shandong Pharmaceutical Glass concludes major syringe project, closes fundraising account

Shandong Pharmaceutical Glass Company (SSE:600529) announced the conclusion and account cancellation for its "Annual Production of 560 Million Prefilled Injection Syringes Expansion and Renovation Project." This project, part of the company's non-public offering, has been fully implemented, with all allocated funds, including interest and wealth management income, utilized. Consequently, the special fundraising account for this project is no longer needed and has been closed, terminating the associated tripartite regulatory agreement.

The non-public offering saw the company issue 68,646,366 A-shares at RMB 27.19 per share, raising a total of RMB 1,866,494,691.54. After deducting issuance expenses of RMB 24,174,380.88, the net proceeds amounted to RMB 1,842,320,310.66. The prefilled syringe project had an investment value of RMB 66,229.08 and saw a cumulative investment of RMB 67,299.57, reflecting an investment progress of 101.62%.

As of the announcement date, the special account for this project had a balance of RMB 0.